Search results for: Multi-Indication Medicines
Filter search results
Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
22 June 2022
…into the next stage of development. In reality, drug developers often require returns to be some positive multiple of costs to recoup the costs of potentially successful and failed investments,…
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
…Antibiotics Part 4: What Does the Antibiotics Market of the Future Look like? References Mott, D.J., Hampson, G., Llewelyn, M.J. et al. A Multinational European Study of Patient Preferences for…
Stuart Carroll
30 August 2023
…mental health, and has published over 150 peer-reviewed academic and scientific papers. Previously, Stuart has worked in consultancy, acted as a Health Policy Adviser to the Conservative Party and undertaken multiple…
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
…transform chronic disease management, delivering value across multiple dimensions. Realising LA therapies’ full potential requires adapting HTA frameworks to reflect their comprehensive benefits, enabling equitable access for patients and incentivising…
Neil McAuslane
9 April 2025
…of work include regulatory strategy and strengthening, building quality into regulatory processes, the utilization of decision frameworks and the development of multistakeholder workshops which bring companies, patients, and agencies (Regulatory…
Around the World in HTAs: Kenya – Riding the Waves of Change
19 May 2025
…is a mixed public and private sector model funded through a multi-payer system i.e. Ministry of Health (MoH), Social Health Authority (SHA), and County Governments. The health system is devolved…
OHE responds to the Trump administration’s Executive Order on Drug Prices
14 May 2025
…with American patients effectively “subsidising” global access to innovative medicines. It appears that this Executive Order aims to reallocate the burden, advancing a narrative similar to that made about NATO…
New evaluation model finds widespread adoption of cell and gene therapies may unlock billions for the UK economy
20 October 2025
…disease (AD) which has multiple cell and gene products in clinical development. In every case identified in the research, substantial economic benefits were demonstrated, beyond individual health gains. These benefits…
Can we “Netflix” the Broken Antibiotics Market?
28 September 2022, 3:00pm
…NHS England to develop and test innovative models for the evaluation and purchase of antimicrobials. David Glover, Deputy Head of the Medicines Analysis Team at NHS England and Improvement David…